« Return to News | CROs/Service Providers

ICON reports quarterly revenue up 5%

Friday, February 17, 2012 01:43 PM

ICON, a global CRO, has reported financial results for the full year and for the fourth quarter ending Dec. 31, 2011.

For the fourth quarter, net revenues grew 5% year on year to $242.6 million and operating income was $6.6 million, representing 3% of revenue, compared to $22 million or 9% for the year-ago quarter. Net income was $4.1 million compared with $22.1 million last year, or $0.07 per share compared to $0.36 in the year-ago quarter.

For the full year 2011, revenue grew 5.1% to $946 million and operating income before non-recurring charges was $39.3 million, representing 4.2% of revenue, compared to $92 million or 10.2% in 2010. On a U.S. GAAP basis, income from operations was $29.4 million, compared with $92 million in the prior year.

Net income before non-recurring charges was $31.5 million, a net margin of 3.3%, compared to $87.1 million and 9.7% of revenue a year ago. EPS before non-recurring charges for 2011 was $0.52 per share, compared with $1.44 in 2010. On a U.S. GAAP basis, net income was $22.8 million, a net margin of 2.4%, compared to $87.1 million and 9.7% of revenue a year ago. EPS on a GAAP basis for 2011 was $0.37 per share compared with $1.44 in 2010.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.